Sort
23,748 grants matching “melanoma”
Targeting Hippo pathway in melanoma
$529,237Xu Wu · Massachusetts General Hospital · R01 · FY2020 · CA
Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy
$529,077Duxin Sun · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy
$529,077Duxin Sun · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Facebook Intervention for Young Onset Melanoma Patients and Families
$529,068Sharon L Manne · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA
TARGETED IMMUNOTHERAPY FOR MELANOMA
$528,801Georgia Tech Research Corp · · FY2016 · Department of the Army
EZH2 in cancer biology and novel inhibitors
$528,530Jun Qi · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer
$528,427Antonio Jimeno · University Of Colorado Denver · R01 · FY2025 · CA
CPTR - Mass Spectrometry Unit
$528,384Lisa Jenkins · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
IL-2 Family Cytokines and their Receptors--Biology of the IL-7/TSLP Systems
$528,158Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL
Facebook Intervention for Young Onset Melanoma Patients and Families
$528,097Sharon L Manne · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
$528,059Craig Lee Slingluff · University Of Virginia · R01 · FY2006 · CA
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
$528,033Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2023 · CA
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL
$527,579Joseph Robert Testa · Research Inst Of Fox Chase Can Ctr · R01 · FY2014 · CA
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL
$527,579Joseph Robert Testa · Research Inst Of Fox Chase Can Ctr · R01 · FY2015 · CA
Translation of commensal bacteria mechanism for immunotherapy
$527,560Howard C Hang · Scripps Research Institute, The · R01 · FY2024 · CA
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER
$527,525Marco Ruella · University Of Pennsylvania · R37 · FY2022 · CA
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER
$527,525Marco Ruella · University Of Pennsylvania · R37 · FY2025 · CA
Role of circular RNA CDR1as in melanoma
$527,415Eva Hernando · New York University School Of Medicine · R01 · FY2023 · CA
Dual-Mechanism Allosteric Inhibitors of ERK Signaling
$527,398Kevin N Dalby · University Of Texas At Austin · R01 · FY2023 · CA
Stromal Regulation of Basal Cell Carcinoma Formation
$527,389Anthony E Oro · Stanford University · R01 · FY2024 · AR
Targeting Lymph Node Dependent Immune Tolerance in Cancer
$527,382Edgar G. Engleman · Stanford University · R01 · FY2023 · CA
An innate immune checkpoint in cancer immunotherapy
$527,107Carla Rothlin · Yale University · R01 · FY2020 · CA
PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRY
$527,013University Of Virginia Charlottesville · R37 · FY2000 · AI
The Framingham School Nevus Study
$526,935Sloan-Kettering Institute For Cancer Res · R01 · FY2005 · AR
Dual-Mechanism Allosteric Inhibitors of ERK Signaling
$526,909Kevin N Dalby · University Of Texas At Austin · R01 · FY2024 · CA